Stillwater Wealth Management Group Acquires New Shares in Amgen Inc. $AMGN

Stillwater Wealth Management Group bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 7,212 shares of the medical research company’s stock, valued at approximately $2,035,000. Amgen makes up about 1.4% of Stillwater Wealth Management Group’s portfolio, making the stock its 29th biggest position.

A number of other institutional investors and hedge funds have also recently made changes to their positions in AMGN. Evelyn Partners Investment Management LLP acquired a new stake in shares of Amgen in the 2nd quarter valued at approximately $32,000. Howard Hughes Medical Institute acquired a new position in Amgen during the 2nd quarter worth approximately $32,000. Cloud Capital Management LLC acquired a new position in Amgen during the 3rd quarter worth approximately $34,000. AXS Investments LLC bought a new position in Amgen in the 3rd quarter valued at approximately $42,000. Finally, Winnow Wealth LLC acquired a new stake in Amgen in the third quarter valued at approximately $47,000. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $351.48 on Thursday. The company has a fifty day moving average price of $359.46 and a 200-day moving average price of $326.94. The company has a market capitalization of $189.47 billion, a P/E ratio of 24.70, a PEG ratio of 3.58 and a beta of 0.45. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the previous year, the business earned $5.31 earnings per share. Amgen’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s payout ratio is presently 70.84%.

Analysts Set New Price Targets

A number of analysts have weighed in on AMGN shares. Citigroup boosted their target price on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Barclays initiated coverage on Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price target for the company. Truist Financial raised their price objective on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a report on Thursday, January 8th. Cantor Fitzgerald upped their target price on Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and a consensus price target of $354.00.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analysts lifted Amgen’s fair value amid optimism around obesity candidate MariTide and execution, which supports a stronger medium-term outlook for earnings. How The Amgen (AMGN) Narrative Is Shifting With MariTide Hopes And Exclusivity Concerns
• Positive Sentiment: Billionaire Ken Fisher increased his Amgen stake, a signal of institutional confidence that can support investor sentiment. Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position
• Neutral Sentiment: Short-interest print shows zero shares (and NaN change), which appears to be a reporting error; it doesn’t offer actionable insight into current positioning.
• Neutral Sentiment: Sector/biotech financing note — Crossbow raised $77M for an oncology T‑cell engager program; industry capital flow can influence sentiment but it doesn’t directly affect Amgen’s fundamentals. Crossbow raises $77M for new cancer immunotherapies
• Negative Sentiment: Report says Amgen will join TrumpRx and offer an ~80% discount on Amjevita — a move that could pressure revenue/margins for that product and raise investor concern about pricing concessions. Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
• Negative Sentiment: Market headlines reporting that AMGN closed lower amid a broader market uptick — confirms the stock is underperforming today and may be reacting to the items above. Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.